Codexis Publishes FY2023 Sustainability Disclosures
Codexis (NASDAQ: CDXS), a leading enzyme engineering company, has published its inaugural sustainability disclosures for fiscal year 2023. These disclosures, aligned with the Sustainability Accounting Standards Board (SASB) guidance, mark a significant milestone in Codexis' sustainability journey. The report covers the company's environmental, social, and governance (ESG) performance for the year ended December 31, 2023.
This initiative demonstrates Codexis' commitment to providing stakeholders with standardized and transparent information about its sustainability efforts. As the company continues to grow as a partner for sustainable drug manufacturing, it plans to build upon these disclosures and make further advancements in its sustainability performance and reporting practices. Interested parties can access Codexis' FY2023 SASB index and learn more about its sustainability program on the company's website.
Codexis (NASDAQ: CDXS), una delle principali aziende nel settore dell'ingegneria enzima, ha pubblicato le sue prime disclosure sulla sostenibilità per l'anno fiscale 2023. Queste disclosure, allineate con le linee guida del Sustainability Accounting Standards Board (SASB), rappresentano un traguardo significativo nel percorso di sostenibilità di Codexis. Il rapporto copre le performance ambientali, sociali e di governance (ESG) dell'azienda per l'anno terminato il 31 dicembre 2023.
Questa iniziativa dimostra l'impegno di Codexis nel fornire agli stakeholder informazioni standardizzate e trasparenti sui propri sforzi in materia di sostenibilità. Mentre l'azienda continua a crescere come partner per la produzione di farmaci sostenibili, intende ampliare queste disclosure e fare ulteriori progressi nelle sue pratiche di performance e reporting sostenibili. Le parti interessate possono accedere all'indice SASB FY2023 di Codexis e scoprire di più sul suo programma di sostenibilità sul sito web dell'azienda.
Codexis (NASDAQ: CDXS), una empresa líder en ingeniería de enzimas, ha publicado sus primeras divulgaciones de sostenibilidad para el año fiscal 2023. Estas divulgaciones, alineadas con las directrices del Sustainability Accounting Standards Board (SASB), marcan un hito significativo en el camino hacia la sostenibilidad de Codexis. El informe abarca el desempeño ambiental, social y de gobernanza (ESG) de la empresa para el año terminado el 31 de diciembre de 2023.
Esta iniciativa demuestra el compromiso de Codexis de proporcionar a las partes interesadas información estandarizada y transparente sobre sus esfuerzos de sostenibilidad. A medida que la empresa continúa creciendo como socio en la fabricación de medicamentos sostenibles, planea construir sobre estas divulgaciones y avanzar en su desempeño y prácticas de informes de sostenibilidad. Las partes interesadas pueden acceder al índice SASB FY2023 de Codexis y conocer más sobre su programa de sostenibilidad en el sitio web de la empresa.
Codexis (NASDAQ: CDXS), 선도적인 효소 공학 회사가 2023 회계 연도에 대한 첫 번째 지속 가능성 공시를 발표했습니다. 이 공시는 Sustainability Accounting Standards Board (SASB)의 지침에 맞춰 Codexis의 지속 가능성 여정에서 중요한 이정표를 나타냅니다. 보고서는 2023년 12월 31일 종료된 해의 회사 환경, 사회, 지배구조 (ESG) 성과를 다루고 있습니다.
이 이니셔티브는 이해관계자에게 지속 가능성 노력에 대한 표준화되고 투명한 정보를 제공하겠다는 Codexis의 의지를 보여줍니다. 회사는 지속 가능한 의약품 제조를 위한 파트너로 성장하며 이러한 공시를 기반으로 하여 지속 가능성 성과와 보고 관행을 더욱 발전시킬 계획입니다. 이해관계자는 Codexis의 FY2023 SASB 지수에 접근하고 회사 웹사이트에서 지속 가능성 프로그램에 대해 더 알아볼 수 있습니다.
Codexis (NASDAQ: CDXS), une entreprise leader dans l'ingénierie enzymatique, a publié ses premières divulgations de durabilité pour l'année fiscale 2023. Ces divulgations, alignées avec les directives du Sustainability Accounting Standards Board (SASB), marquent une étape importante dans le parcours de durabilité de Codexis. Le rapport couvre la performance environnementale, sociale et de gouvernance (ESG) de l'entreprise pour l'année se terminant le 31 décembre 2023.
Cette initiative démontre l'engagement de Codexis à fournir aux parties prenantes des informations standardisées et transparentes sur ses efforts en matière de durabilité. Alors que l'entreprise continue de croître en tant que partenaire pour la fabrication de médicaments durables, elle prévoit de s'appuyer sur ces divulgations et de réaliser d'autres avancées dans ses performances et pratiques de reporting en matière de durabilité. Les parties intéressées peuvent accéder à l'indice SASB FY2023 de Codexis et en savoir plus sur son programme de durabilité sur le site Web de l'entreprise.
Codexis (NASDAQ: CDXS), ein führendes Unternehmen in der Enzymtechnik, hat seine ersten Nachhaltigkeitsberichte für das Geschäftsjahr 2023 veröffentlicht. Diese Berichte, die den Richtlinien des Sustainability Accounting Standards Board (SASB) entsprechen, markieren einen bedeutenden Meilenstein auf dem Nachhaltigkeitsweg von Codexis. Der Bericht behandelt die Umwelt-, Sozial- und Governance (ESG)-Leistung des Unternehmens für das am 31. Dezember 2023 endende Jahr.
Diese Initiative zeigt Codexis' Engagement, den Stakeholdern standardisierte und transparente Informationen über seine Nachhaltigkeitsbemühungen zur Verfügung zu stellen. Da das Unternehmen weiterhin als Partner für nachhaltige Arzneimittelherstellung wächst, plant es, auf diesen Berichten aufzubauen und weitere Fortschritte in seiner Nachhaltigkeitsleistung und Berichterstattung zu erzielen. Interessierte können das FY2023 SASB-Index von Codexis einsehen und mehr über das Nachhaltigkeitsprogramm auf der Unternehmenswebsite erfahren.
- None.
- None.
Inaugural ESG Disclosures Align with the Sustainability Accounting Standards Board
REDWOOD CITY, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the publication of its inaugural sustainability disclosures detailing the Company’s environmental, social, and governance (“ESG”) performance for the fiscal year ended December 31, 2023. The disclosures are aligned with guidance provided by the International Financial Reporting Standards’ (“IFRS”) Sustainability Accounting Standards Board (“SASB”). This marks an important step in Codexis’ sustainability journey and bolsters its efforts to provide stakeholders with important disclosures in a clear and standardized manner.
As Codexis continues its growth as a partner of choice for sustainable drug manufacturing, the Company looks forward to building upon today's disclosures and making meaningful advancements in its sustainability performance and future reporting. To learn more about Codexis’ sustainability program or obtain a copy of Codexis’ FY2023 SASB index, please visit the Company’s website.
About Codexis
Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit www.codexis.com.
Forward-Looking Statements
This press release includes “forward-looking statements,” as the term is defined under the federal securities laws. Forward-looking statements are those statements that are not statements of historical fact. Forward-looking statements can be identified by forward-looking words such as “expects,” “anticipates,” “intends,” “plans,” “may,” “will,” “believes,” “seeks,” “estimates,” and similar expressions. These statements are based on management’s current opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, including, but not limited to, our ESG commitments, strategies and initiatives; our business plans and strategy; our products, services and solutions; and our stakeholder engagement efforts. These forward-looking statements are only predictions, not historical fact, and involve certain risks and uncertainties, as well as assumptions. Actual results, levels of activity, performance, achievements and events could differ materially from those stated, anticipated or implied by such forward-looking statements. While Codexis believes that its assumptions are reasonable, it is very difficult to predict the impact of known factors and it is impossible to anticipate all factors that could affect actual results. There are many risks and uncertainties that could cause actual results to differ materially from forward-looking statements herein including, most prominently, the risks discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 28, 2024 and in the Company’s Quarterly Report on Form 10-Q filed with the SEC on August 8, 2024, including under the caption “Risk Factors,” and in Codexis’ other periodic reports filed with the SEC. Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com
Media Contact
Lauren Musto
(650) 421-8205
media@codexis.com
FAQ
What did Codexis (CDXS) announce on August 15, 2024?
Which standards did Codexis (CDXS) follow for its 2023 sustainability disclosures?
What period does Codexis' (CDXS) first sustainability report cover?
Where can investors find Codexis' (CDXS) FY2023 SASB index?
What is Codexis' (CDXS) main business focus?
